Cannabinoids, alkaloids, tryptamines, ergolines, retinol, functional natural dyes, peptides, and more. Compounds for mental health, non-opioid pain, healthy aging, and what medicine still needs.
“A cleaner question for kratom-class pain biology.”
Korvane is our non-opioid pain research program, focused on a precision blend of minor kratom alkaloids selected away from dominant extract chemistry. Produced through a mixed route: yeast fermentation where the pathway allows, downstream chemistry where it does not.
Visit Korvane
“Animal-free by construction. Standardized by design.”
Aevora is our peptide-enriched yeasted extract program. Precision fermentation produces the compounds behind modern healthspan, longevity, weight-loss, and hair-regrowth work, without animal-source material or stepwise chemical synthesis.
Visit Aevora
“Every run teaches the next one.”
The data and AI layer behind the platform. Every fermentation run generates training data that sharpens the agentic AI. The feedback loop between lab results and model predictions tightens strain design from months to weeks.
Visit TryptageniX AI
Sher Ali Butt joins host George Monty on the TrueLife Podcast for a full-length conversation on yeast biosynthesis across cannabinoids, tryptamines, ergolines, and food-tech compounds, and the science behind CB Therapeutics' precision-fermentation platform.
TrueLife Podcast
Co-founder & CSO Jacob Vogan joined Andrew Jones (Miami), Peter Facchini (Calgary), and Victoria Costa Paz (Eywa Biotech) in San Jose to compare fermentation, chemical synthesis, and extraction routes for psychedelic and psychedelic-inspired therapeutics.
SynBioBeta 2025
The yeast-based precision-fermentation platform expands into ergoline-class alkaloids, with applications across neurology, migraine, Parkinson's, and psychiatric research. Full title: CB Therapeutics Breaks Ground on Sustainable Ergoline Biosynthesis Through Precision Fermentation.
AccessWire
CB Therapeutics joins the small cohort of biotech companies producing pharma- and cosmetic-grade retinol (vitamin A) through precision fermentation, with applications across pharmaceutical and cosmetic formulation.
Newsfilecorp
In-house downstream processing reaches 99.6% purity on rare cannabinoids like CBC, produced at the 16,000 sq ft Southern California facility.
BusinessWire
Industry feature by Mohamed Soufi profiling CB Therapeutics' precision-fermentation approach, with CEO Sher Ali Butt on mushroom psilocybin yields (~1%), the waste burden of chemical synthesis (~10 kg per kg product), and how the platform has reduced development timelines compared with extraction or total chemical synthesis.
SynBioBeta
Natural food and cosmetic colorants (β-carotene, betalains, lycopene, lutein) and antioxidants produced via precision fermentation. Applications across food and cosmetic formulation.
BusinessWire
CEO Sher Ali Butt joined Dr. Amy Reichelt, Jason Najum, and Dr. Sam Clark on the Explore Stage at Wonderland Miami, a global gathering on psychedelics, mental health, and longevity, for a panel on designing the next generation of safer psychoactives.
Wonderland Miami
Jacob Vogan joins Deep Tech Show for a 31-minute conversation on precision synthetic biology: the YC journey, engineering microorganisms, the 16,000 sq ft Carlsbad, CA lab, and the platform's compound scope.
Deep Tech Show
Ghana's JoyNews speaks with Jacob Vogan over Zoom about the precision-fermentation platform and its compound pipeline.
Precision fermentation applied beyond pharmaceuticals: natural colors, antioxidants, and flavor molecules, produced on the yeast platform built for cannabinoids.
SDBJ editorial coverage of the tryptamine biosynthesis patent grant, independent from the wire press release. Reports on the IP milestone and what tryptamine biosynthesis could mean for psychedelic-medicine research.
Local business profile in SDBJ covering the move into 16,000 sq ft in Carlsbad, the team scaling from 21 to 26, and the pipeline across cannabinoids and tryptamines.
Patent granted covering microbial production of tryptamines and their analogs, including psilocybin and related compounds of the magic-mushroom family.
16,000 sq ft of research and production space in Southern California, supporting cannabinoid and tryptamine production alongside R&D for adjacent compound classes.
Dr. Stephen Wright and Dr. Brian Barnett join the Medical Advisory Board, bringing clinical expertise to the biosynthesis platform.
Multiple psychedelic-sector outlets covered the TryptageniX launch as a major industry event, with NXTpsychedelics, Psilocybin Alpha, and others featuring CB Therapeutics and Sher Ali Butt.
Editorial analysis of the TryptageniX launch covering the joint venture structure with ATAI Life Sciences, the bioprospecting strategy, and the biosynthetic manufacturing approach for new chemical entities in mental health.
A dedicated AI-guided program for rare-alkaloid design, aimed at mental-health applications. TryptageniX is wholly CBT-owned.
Dedicated editorial profile of CB Therapeutics on the leading psychedelic-research publication. Covers the precision-fermentation platform, patent portfolio, and co-founders Sher Ali Butt and Jacob Vogan.
Two granted USPTO patents expanding the platform's cannabinoid coverage: optimized terpene-precursor sequences feeding cannabinoid flux, and malonate transporter enzymes that increase intracellular malonyl-CoA flux for cannabinoid biosynthesis.
Series A led by Christian Angermayer's re.Mind Capital (Apeiron). The round funded parallel work across cannabinoids and psychedelics.
Sher Ali Butt on cannabinoid and tryptamine biosynthesis: the same yeast platform producing two classes of compounds.
In-house downstream processing reaches 95% purity on rare cannabinoids, bringing fermentation output to a characterized, research-grade compound.
First delivery of fermentation-produced rare cannabinoids to an external research client in Colorado, validating the downstream processing workflow outside the CBT lab.
Sher Ali Butt joins CFN Media for a video interview on the platform's expansion into psychedelics, two weeks after the yeast-made DMT announcement.
Six months after psilocybin, DMT becomes the second tryptamine produced in yeast, at research-grade purity.
Patent covering automated cloud-based genome-and-transcriptome assembly, the bioinformatics pipeline behind the platform's compound design work.
MOU signed to provide research-use samples of psilocybin, DMT, and MDMA to Cleveland Clinic for depression, addiction, and PTSD studies.
Yeast-based biosynthesis of psilocybin, the active compound of the magic-mushroom family. The fermentation platform extends to a second compound class within a year of the cannabinoid work; the psilocybin pathway was later codified in a granted USPTO patent in 2022.
Codon-optimized nucleic acids covering the biosynthetic cannabinoid pathway in S. cerevisiae. The core inventions behind yeast-based cannabinoid production.
Initial patent applications filed, covering core inventions in sugar-to-cannabinoid biosynthesis.
Production numbers meet mid-year targets, validating the yeast platform's output ahead of the full-year milestone.
Capital to move cannabinoid biosynthesis from proof-of-concept to pilot bioreactor, funding the lab buildout and the first production-scale fermenter.
A dedicated research and production facility opens, providing the space and infrastructure to scale biosynthesis work.
The San Diego Union-Tribune profiles the Carlsbad team engineering yeast to produce cannabinoids, bypassing plant cultivation and extraction.
Startup Battlefield finalist at Disrupt SF 2018, with a standalone TechCrunch feature by Devin Coldewey profiling the yeast platform.
TechCrunch names CB Therapeutics one of the top 10 companies from YC's Summer 2018 batch.
